Viral Vector Manufacturing Facility Pty Ltd (VVMF) and Chimeric Therapeutics (ASX:CHM, “Chimeric”) have cosigned a Letter of Intent (LOI) to enter a strategic supplier relationship focused on the development and GMP grade manufacturing of Lentiviral vectors (LV).
Under the LOI, VVMF will support process development, technology transfer, and GMP manufacturing of Lentiviral vectors for Chimeric’s clinical stage chimeric antigen receptor (CAR-T) program. Viral vectors are a critical component in the production of CAR-T therapies, which are transforming cancer treatment globally.
This partnership marks a significant step forward in strengthening Australia’s advanced manufacturing capabilities and the development of Advanced Therapy Medicinal Products (ATMPs). ATMPs are innovative medicines derived from genes, cells, or tissue engineering. They often involve living cells or tissues, requiring highly specialised manufacturing and handling. These therapies offer new treatment possibilities for a range of diseases, including cancer, neurodegenerative disorders, and cardiovascular conditions.
Australia is recognised globally for its support of early-stage biotech companies with significant R&D tax incentives for eligible activities, a globally recognised and pragmatic regulatory environment, and access to a mature clinical trial ecosystem. This collaboration will enhance access to cutting-edge therapies for both Australian and international patients with expanded local clinical trial sites.
Stephen Thompson, VVMF CEO, said: “We are excited to be supporting Chimeric’s clinical development program as Australia’s first and only commercial-scale viral vector manufacturer. This collaboration strengthens sovereign advanced manufacturing, supports the creation of high value jobs in Western Sydney, and allows us to demonstrate our capability to develop and manufacture GMP-grade viral vectors for the global cell and gene therapy marketplace.”
Dr Rebecca McQualter, Chimeric Therapeutics CEO, said: “We’re pleased to partner with VVMF as we continue to advance our CAR-T cell therapy programs. Having access to local, GMP-grade viral vector manufacturing not only strengthens our supply chain but also supports the broader goal of building world-class advanced therapy capabilities here in Australia.”